Core Viewpoint - TransCode Therapeutics Inc. (RNAZ) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [2][4]. - Rising earnings estimates for TransCode Therapeutics suggest an improvement in the company's underlying business, likely leading to increased stock prices [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of TransCode Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, TransCode Therapeutics is expected to earn -$1.63 per share, reflecting a 96.5% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for TransCode has increased by 62.7%, highlighting a positive trend in earnings estimates [8].
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy